Abstract
Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives Candida auris is an emerging yeast pathogen with worldwide distribution and a great propensity for nosocomial spread. Recent reports have warned of the significant emergence of C. auris in several healthcare facilities. In order to stop its nosocomial transmission, use of antiseptics constitutes the first-line lever of action in fighting against C. auris skin colonization. However, little is known about the efficacy of these products, and moreover, no antiseptics are currently registered for use against C. auris.Material and MethodsThis study investigated the in vitro yeasticidal activity of povidone-iodine (Betadine®) against C. auris, and compared the findings to C. albicans and C. glabrata.ResultsIn all the samples, the fungal load was substantially reduced by ≥4.2 Log10 colony-forming units, according to the EN standard 1275:2005. Moreover, even when largely diluted, povidone-iodine products still allowed a sustainable decrease of the yeast viability below 0.1%.ConclusionOverall, these results support the use of such commercial antiseptics in the context of colonization with this yeast.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
